Insulet (PODD) Ends April With Strong Analyst Sentiment Amid Strong Earnings Expectations

With one-year EPS and gross maturation estimates of 27.44% and 19.19%, respectively, Insulet Corporation (NASDAQ:PODD) earns a spot connected our database of the best maturation stocks to bargain and clasp successful 2026.

Cherries/Shutterstock.com

Insulet Corporation (NASDAQ:PODD) is heading into precocious April 2026 with beardown expert backing. As of April 23, the bulk of analysts covering the banal person a Buy standing connected it, and the statement terms people of $360 points to 87% upside potential.

On April 15, 2026, Truist expert Richard Newitter lowered the firm’s terms people connected Insulet Corporation (NASDAQ:PODD) to $315 from $360, a measured revision that did small to shingle his wide conviction.

Newitter kept the firm’s Buy standing firmly successful place, noting that first-quarter results are expected to travel successful enactment oregon better, adjacent arsenic capitalist sentiment astir volumes stays connected the cautious side. He noted that Insulet Corporation (NASDAQ:PODD) presently trades astatine a flimsy discount to its adjacent radical of high-growth profitable companies but argued it should commercialized astatine slightest successful enactment with peers, if not astatine a premium, fixed its stronger gross and nett maturation profile.

That constructive presumption builds connected Insulet’s 4th fourth results.

Revenue came successful astatine $783.8 million, up 31.2% (29.0% successful changeless currency), exceeding the company’s guidance. Omnipod delivered maturation successful the quarter, with full gross reaching $781.8 million, up 33.5% year-over-year. In the U.S., gross reached $567.8 million, up 28.0%, portion planetary gross grew astatine an adjacent stronger rate, rising 50.7% to $214 million.

For the afloat year, gross grew 30.7% to $2.7 billion, and adjusted nett income came successful astatine $354.4 million, oregon $4.97 per diluted share.

Looking up to 2026, Insulet Corporation (NASDAQ:PODD) is guiding for first-quarter full gross maturation of 25% to 27%, with full-year maturation of 20% to 22%. Omnipod is targeted to turn a spot faster, with projected first-quarter maturation of 28% to 30% and full-year maturation of 21% to 23%. Rounding retired the guidance, the institution is projecting astir 100 ground points of borderline expansion, and adjusted EPS maturation is expected to transcend 25%.

Insulet Corporation (NASDAQ:PODD) is simply a aesculapian instrumentality institution that develops, markets, and manufactures an insulin infusion strategy for radical with insulin-dependent diabetes. The institution specializes successful diabetes supplies, on with different diabetes related products and supplies, including pump supplies, accepted insulin pumps, humor glucose investigating supplies, and pharmaceuticals.

While we admit the imaginable of PODD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.